SIV DNA VACCINES AND MUCOSAL IMMUNITY

SIV DNA 疫苗和粘膜免疫

• 批准号: 8172802
• 负责人: ANNA ALDOVINI
• 金额: $ 6.58万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172802
• 关键词: AIDS Vaccines; AIDS vaccine development; Computer Retrieval of Information on Scientific Projects Database; DNA; DNA Vaccines; Development; Disadvantaged; Funding; Grant; HIV; HIV Infections; Immunologic Deficiency Syndromes; Infection; Institution; Mucosal Immunity; Recombinants; Research; Research Personnel; Resources; Route; SIV; Source; United States National Institutes of Health; Vaccination; Vaccines; Vaccinia; transmission process; vaccine candidate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SIV DNA vaccines and mucosal immunity More than 80 percent of global transmission of HIV infection occurs via mucosal routes. The ability of vaccines to induce mucosal immunity may be required for protection against HIV infection and the immunodeficiency syndrome that emerges after infection. Various AIDS vaccine candidates are currently under development, each with potential advantages and disadvantages. DNA vaccines have features that make them attractive vaccine candidates for HIV and the combination of DNA vaccination plus recombinant vaccinia is one of the favored approaches in AIDS vaccine development.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 SIV DNA疫苗与粘膜免疫 全球80%以上的艾滋病毒感染是通过粘膜途径传播的。 疫苗诱导粘膜免疫的能力可能是预防HIV感染和感染后出现的免疫缺陷综合征所必需的。 目前正在开发各种艾滋病候选疫苗，每种疫苗都有潜在的优点和缺点。DNA疫苗的特性使其成为HIV的有吸引力的疫苗候选物，并且DNA疫苗接种与重组牛痘的组合是AIDS疫苗开发中受欢迎的方法之一。